| Year |
Citation |
Score |
| 2016 |
Zhang R, Wu J, Ferrandon S, Glowacki KJ, Houghton JA. Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing. Oncotarget. PMID 27863397 DOI: 10.18632/oncotarget.13376 |
0.497 |
|
| 2014 |
Agyeman A, Jha BK, Mazumdar T, Houghton JA. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget. 5: 4492-503. PMID 24962990 DOI: 10.18632/oncotarget.2046 |
0.513 |
|
| 2014 |
Agyeman A, Jha BK, Mazumder T, Houghton JA. Abstract 1759: Targeting GLI-dependent transcription by GANT61 in human colon carcinoma cells (CC); a new therapeutic approach Cancer Research. 74: 1759-1759. DOI: 10.1158/1538-7445.Am2014-1759 |
0.39 |
|
| 2013 |
Mazumdar T, Sandhu R, Qadan M, DeVecchio J, Magloire V, Agyeman A, Li B, Houghton JA. Hedgehog signaling regulates telomerase reverse transcriptase in human cancer cells. Plos One. 8: e75253. PMID 24086482 DOI: 10.1371/Journal.Pone.0075253 |
0.479 |
|
| 2013 |
Agyeman A, Mazumder T, Houghton J. Abstract 669: A unique acquired resistance mechanism to agents that target GLI (GANT61) in the Hedgehog (HH) signaling pathway in human colon cancer cells. Cancer Research. 73: 669-669. DOI: 10.1158/1538-7445.Am2013-669 |
0.398 |
|
| 2012 |
Agyeman A, Mazumdar T, Houghton JA. Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget. 3: 854-68. PMID 23097684 DOI: 10.18632/oncotarget.586 |
0.426 |
|
| 2011 |
Mazumdar T, DeVecchio J, Agyeman A, Shi T, Houghton JA. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget. 2: 638-45. PMID 21860067 DOI: 10.18632/oncotarget.310 |
0.546 |
|
| 2011 |
Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Research. 71: 5904-14. PMID 21747117 DOI: 10.1158/0008-5472.CAN-10-4173 |
0.563 |
|
| 2011 |
Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Research. 71: 1092-102. PMID 21135115 DOI: 10.1158/0008-5472.CAN-10-2315 |
0.48 |
|
| 2010 |
Shi T, Mazumdar T, Devecchio J, Duan ZH, Agyeman A, Aziz M, Houghton JA. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. Plos One. 5. PMID 20957031 DOI: 10.1371/journal.pone.0013054 |
0.358 |
|
| 2010 |
Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. The Journal of Biological Chemistry. 285: 19162-72. PMID 20424169 DOI: 10.1074/jbc.M109.091645 |
0.429 |
|
| 2008 |
Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 112: 2917-26. PMID 18641367 DOI: 10.1182/Blood-2007-12-130823 |
0.375 |
|
| 2008 |
Lobo GP, Waite KA, Planchon SM, Romigh T, Houghton JA, Eng C. ATP modulates PTEN subcellular localization in multiple cancer cell lines. Human Molecular Genetics. 17: 2877-85. PMID 18579579 DOI: 10.1093/Hmg/Ddn185 |
0.357 |
|
| 2008 |
Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA, Marton LJ, Cleveland JL. The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Research. 68: 4783-90. PMID 18559525 DOI: 10.1158/0008-5472.Can-07-6483 |
0.362 |
|
| 2007 |
Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Research. 67: 6987-94. PMID 17638911 DOI: 10.1158/0008-5472.Can-07-0812 |
0.427 |
|
| 2007 |
Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 110: 313-22. PMID 17363733 DOI: 10.1182/Blood-2006-10-050260 |
0.371 |
|
| 2006 |
Nagy K, Székely-Szüts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhász H, Dominici M, Spano C, Luca Cervo G, Conte P, Houghton JA, Mihalik R, Kopper L, Peták I. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathology Oncology Research : Por. 12: 133-42. PMID 16998592 DOI: 10.1007/Bf02893359 |
0.348 |
|
| 2005 |
Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Research. 65: 11447-58. PMID 16357153 DOI: 10.1158/0008-5472.CAN-05-1494 |
0.379 |
|
| 2005 |
Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene. 24: 2050-8. PMID 15688023 DOI: 10.1038/sj.onc.1208397 |
0.335 |
|
| 2004 |
Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA. P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Cancer Research. 64: 6296-303. PMID 15342418 DOI: 10.1158/0008-5472.CAN-04-0863 |
0.43 |
|
| 2003 |
Geller J, Petak I, Szucs KS, Nagy K, Tillman DM, Houghton JA. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 6504-15. PMID 14695155 |
0.352 |
|
| Show low-probability matches. |